Doxazosin: Effective Blood Pressure and BPH Management
| Product dosage: 1 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.39 | $46.31 (0%) | 🛒 Add to cart |
| 180 | $0.35 | $69.46 $62.42 (10%) | 🛒 Add to cart |
| 270 | $0.32 | $104.19 $86.58 (17%) | 🛒 Add to cart |
| 360 | $0.31
Best per pill | $138.93 $110.74 (20%) | 🛒 Add to cart |
| Product dosage: 2 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.33 (0%) | 🛒 Add to cart |
| 90 | $0.69 | $73.99 $62.42 (16%) | 🛒 Add to cart |
| 120 | $0.63 | $98.66 $75.50 (23%) | 🛒 Add to cart |
| 180 | $0.57 | $147.99 $102.68 (31%) | 🛒 Add to cart |
| 270 | $0.53 | $221.98 $141.95 (36%) | 🛒 Add to cart |
| 360 | $0.51
Best per pill | $295.97 $182.21 (38%) | 🛒 Add to cart |
| Product dosage: 4 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.41 | $42.28 (0%) | 🛒 Add to cart |
| 60 | $1.14 | $84.56 $68.46 (19%) | 🛒 Add to cart |
| 90 | $1.06 | $126.85 $95.64 (25%) | 🛒 Add to cart |
| 120 | $1.02 | $169.13 $121.81 (28%) | 🛒 Add to cart |
| 180 | $0.97 | $253.69 $175.17 (31%) | 🛒 Add to cart |
| 270 | $0.94 | $380.54 $254.70 (33%) | 🛒 Add to cart |
| 360 | $0.93
Best per pill | $507.38 $334.23 (34%) | 🛒 Add to cart |
Synonyms | |||
Doxazosin is a selective alpha-1 adrenergic receptor antagonist belonging to the quinazoline class. It is primarily indicated for the management of hypertension, both as monotherapy and in combination with other antihypertensive agents, and for the treatment of symptomatic benign prostatic hyperplasia (BPH). Its mechanism of action involves relaxation of vascular smooth muscle, leading to peripheral vasodilation and reduced blood pressure, and relaxation of smooth muscle in the prostate and bladder neck, improving urinary flow. This dual therapeutic profile makes it a versatile agent in cardiovascular and urological medicine, requiring careful patient selection and monitoring to optimize therapeutic outcomes and minimize adverse effects.
Features
- Selective alpha-1 adrenergic receptor antagonist
- Available in standard and extended-release (XL) tablet formulations
- Administered via oral route, typically once daily
- Metabolized extensively in the liver via cytochrome P450 3A4 (CYP3A4)
- Exhibits an elimination half-life of approximately 22 hours
- Excreted primarily in feces (approx. 63%) and urine (approx. 9%)
Benefits
- Provides effective reduction in both systolic and diastolic blood pressure.
- Improves urinary flow rates and reduces symptoms of benign prostatic hyperplasia, such as hesitancy, weak stream, and nocturia.
- Offers a favorable hemodynamic profile, reducing peripheral vascular resistance without significantly affecting cardiac output.
- Can be used as part of a combination antihypertensive regimen.
- The extended-release formulation allows for convenient once-daily dosing, potentially improving adherence.
- Does not adversely affect blood lipid profiles or glucose metabolism.
Common use
Doxazosin is commonly prescribed for two primary indications. First, for the management of hypertension, where it is used to lower elevated blood pressure, either as a single agent or, more commonly, in combination with other drug classes such as diuretics, ACE inhibitors, or calcium channel blockers. Second, it is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), where it works to relax the smooth muscle of the prostate and bladder neck, thereby decreasing bladder outlet obstruction and improving urine flow. It is not indicated for the treatment of hypertension in children.
Dosage and direction
Dosing must be individualized based on the patient’s therapeutic response and tolerability. For hypertension, the initial dose is 1 mg administered once daily. The dose may be increased gradually, typically at 1-2 week intervals, to 2 mg, 4 mg, 8 mg, and finally to a maximum of 16 mg once daily, based on blood pressure response. The majority of patients respond to doses of 4 mg to 8 mg daily. For Benign Prostatic Hyperplasia (BPH), the initial dose is also 1 mg once daily. The dose may be titrated to 2 mg, 4 mg, and 8 mg once daily, with the recommended therapeutic dose range being 4-8 mg daily. The extended-release formulation (doxazosin XL) is initiated at 4 mg once daily and may be increased to 8 mg once daily. All formulations should be taken with the morning or evening meal. The initial dose must be 1 mg for all patients to minimize the risk of a pronounced first-dose effect (e.g., syncope). Patients should be advised to take their dose at the same time each day.
Precautions
First-dose Effect: Marked hypotension, syncope, and postural dizziness with or without syncope can occur within 2-6 hours of the first dose or any subsequent rapid dose increase. This risk is increased by dehydration, salt depletion, and concurrent use of other antihypertensive agents. Orthostatic Hypotension: Doxazosin can cause a significant drop in blood pressure upon standing, especially after the initial dose. Patients should be cautioned to avoid situations where injury could result from syncope. Priapism: Although rare, prolonged and painful erections (priapism) have been reported. This condition requires immediate medical attention to prevent permanent erectile dysfunction. Cataract Surgery: A complication known as Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in patients treated with alpha-1 blockers. Ophthalmologists should be informed of a patient’s use of doxazosin prior to surgery. Hepatic Impairment: Doxazosin should be administered with caution to patients with evidence of impaired liver function, as the drug is extensively metabolized by the liver. Prostate Cancer: Patients with BPH should be evaluated to rule out the presence of prostate carcinoma before initiating therapy with doxazosin, as the drug does not treat malignancy.
Contraindications
Doxazosin is contraindicated in patients with a known hypersensitivity to doxazosin, other quinazolines (e.g., prazosin, terazosin), or any component of the formulation. Its use is also contraindicated in patients with a history of orthostatic hypotension and as a treatment for congestive heart failure.
Possible side effect
Common side effects (≥2%) include:
- Dizziness (15.6%)
- Fatigue (8.1%)
- Headache (5.6%)
- Somnolence (drowsiness) (3.9%)
- Nausea (3.5%)
- Edema (peripheral edema) (2.9%)
- Rhinitis (2.6%)
- Hypotension, postural hypotension (2.2%)
- Dyspnea (2.1%)
Less common but serious side effects include:
- Syncope (fainting) (0.7%)
- Palpitations
- Tachycardia (rapid heart rate)
- Priapism
- Signs of angina pectoris
- Symptoms of a severe allergic reaction (e.g., rash, hives, swelling)
Drug interaction
Doxazosin has the potential to interact with several other medications:
- Other Antihypertensives (e.g., diuretics, beta-blockers, ACE inhibitors, calcium channel blockers): Concomitant use may result in excessively low blood pressure (additive hypotensive effects). Careful titration and blood pressure monitoring are required.
- Phosphodiesterase-5 Inhibitors (e.g., sildenafil, tadalafil, vardenafil): These drugs also have vasodilatory properties and can potentiate the hypotensive effects of doxazosin, leading to symptomatic hypotension. Concurrent use is not recommended.
- Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin): These drugs can significantly increase the plasma concentration of doxazosin, increasing the risk of adverse effects, including hypotension. Concomitant use should be approached with caution, and a dose reduction of doxazosin may be necessary.
- NSAIDs (e.g., ibuprofen, naproxen): Nonsteroidal anti-inflammatory drugs may reduce the antihypertensive effect of doxazosin by causing fluid retention and decreased renal function.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is not remembered until the next day, the patient should skip the missed dose and resume the usual dosing schedule. The dose should not be doubled to make up for a missed dose.
Overdose
In the event of an overdose, the primary expected manifestation is profound hypotension, which may present as dizziness, lightheadedness, or syncope. Supportive care is the mainstay of treatment. This includes placing the patient in a supine position, elevating the legs, and administering intravenous fluids to restore blood pressure and support circulation. Vasopressors may be used if necessary. Gastric lavage or activated charcoal may be considered if ingestion was very recent. Due to its high protein binding, doxazosin is not dialyzable.
Storage
Store doxazosin tablets at room temperature, between 20°C to 25°C (68°F to 77°F), in a tightly closed container. Protect from light, moisture, and excessive heat. Keep all medications out of the reach of children and pets.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
- “As a cardiologist, I find doxazosin to be a useful add-on agent for resistant hypertension, particularly in patients with concomitant BPH. The key is a slow, careful titration to mitigate first-dose syncope.” – Dr. A. Reynolds, MD
- “The doxazosin XL formulation has improved patient adherence in my urology practice. The once-daily dosing is convenient, and patients report a noticeable improvement in urinary symptoms within a few weeks.” – Dr. L. Chen, MD
- “Effective for its indications, but requires diligent patient education regarding the risks of orthostasis, especially in the elderly population. The drug interaction profile necessitates a thorough review of a patient’s medication list.” – Clinical Pharmacist Review
- “A well-established option in the alpha-blocker class. Its long half-life is a distinct advantage, providing 24-hour coverage. Monitoring during the initial titration phase is critical for patient safety.” – Cardiology Today Journal